Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$30.61 USD
-0.21 (-0.68%)
Updated May 20, 2024 02:17 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 101 - 120 ( 718 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April Preliminary Sales: Looking to May for Growth to Pick Up Momentum
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
1Q22: Solid Q vs. Our Estimates; Industry Macro Headwinds Are Long-Term Exparel Tailwinds, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1: EXPAREL Growth In-tact Despite Market Headwinds; Pipeline Expansion
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Prelim Sales: Record March Exparel Sales Set the Tone for Growth in 2022
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
February Preliminary Sales Put EXPAREL Growth Back On-Track
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4/FY:21: EXPAREL Growth Intact as ZILRETTA and iovera Come into Sharper Focus
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
4Q21: Record Operating Margin (Again); Raise PT to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
January 2022 Prelim Sales: Looking Ahead for Growth to Continue
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Prelim FY21 Revenue Supports EXPAREL Growth Despite Pandemic Headwinds
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L